Johnson & Johnson has agreed to acquire Ollin Biosciences in a deal valued at up to about $3.33 billion.
J&J will pay $2.2 billion upfront, with up to approximately $1.13 billion more tied to regulatory and commercial milestones.
The acquisition adds OLN324, an investigational Phase 3 bispecific antibody targeting VEGF and Ang2, being developed for wet age-related macular degeneration and diabetic macular edema—retinal diseases that can cause vision loss.
Separately, Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 development after the acquisition closes; Blackstone may receive milestones and single-digit royalties.
The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Sources:
J&J to buy eye disease biotech Ollin Biosciences for up to ...
J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT ...
J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says
Johnson & Johnson to acquire Ollin Biosciences and late- ...
J&J to buy eye disease biotech Ollin Biosciences for up to $3.3
J&J to Buy Ollin for $3.33 Billion to Expand in Eye Disease ...
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
Johnson & Johnson Agrees to Buy Ollin Biosciences in Up to $3.33 Billion Deal
J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says
Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says
J&J cuts $3.3bn deal to buy eye drug developer Ollin
Ollin Biosciences and Its Next-Generation Medicines for ...
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports